- Home
- MRNA
MRNA
Moderna Inc.
as 07-26-2024 4:00pm EST
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Upcoming Earnings Alert:
Get ready for potential market movements as Moderna Inc. MRNA prepares to release earnings report on 01 Aug 2024.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 54.0B | IPO Year: | 2018 |
| Target Price: | $142.86 | AVG Volume (30 days): | 2.8M |
| Analyst Decision: | Buy | Number of Analysts: | 16 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -15.66 | EPS Growth: | N/A |
| 52 Week Low/High: | $62.55 - $170.47 | Next Earning Date: | 08-01-2024 |
| Revenue: | $5,153,000,000 | Revenue Growth: | -65.78% |
| Revenue Growth (this year): | -38.3% | Revenue Growth (next year): | 13.37% |
Stock Insider Trading Activity of Moderna Inc. (MRNA)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Hoge Stephen | MRNA | President | Jul 15 '24 | Sell | $121.12 | 15,000 | $1,816,800.00 | 1,442,089 | SEC Form 4 |
| Mock James M | MRNA | Chief Financial Officer | Jul 5 '24 | Sell | $118.24 | 689 | $81,465.36 | 7,269 | SEC Form 4 |
| AFEYAN NOUBAR | MRNA | Director | Jun 26 '24 | Sell | $122.69 | 2,460 | $301,814.20 | 2,296,555 | SEC Form 4 |
| AFEYAN NOUBAR | MRNA | Director | Jun 26 '24 | Sell | $123.74 | 1,600 | $197,978.08 | 2,294,955 | SEC Form 4 |
| AFEYAN NOUBAR | MRNA | Director | Jun 26 '24 | Sell | $124.90 | 1,500 | $187,352.25 | 2,293,455 | SEC Form 4 |
| AFEYAN NOUBAR | MRNA | Director | Jun 26 '24 | Sell | $125.71 | 1,100 | $138,277.04 | 2,292,355 | SEC Form 4 |
| AFEYAN NOUBAR | MRNA | Director | Jun 26 '24 | Sell | $127.50 | 1,100 | $140,253.85 | 2,291,255 | SEC Form 4 |
| AFEYAN NOUBAR | MRNA | Director | Jun 26 '24 | Sell | $128.78 | 1,435 | $184,797.72 | 2,289,820 | SEC Form 4 |
| AFEYAN NOUBAR | MRNA | Director | Jun 26 '24 | Sell | $129.84 | 2,300 | $298,631.31 | 2,287,520 | SEC Form 4 |
| AFEYAN NOUBAR | MRNA | Director | Jun 26 '24 | Sell | $130.76 | 2,705 | $353,694.98 | 2,284,815 | SEC Form 4 |
| AFEYAN NOUBAR | MRNA | Director | Jun 26 '24 | Sell | $131.56 | 700 | $92,088.99 | 2,284,115 | SEC Form 4 |
| AFEYAN NOUBAR | MRNA | Director | Jun 26 '24 | Sell | $134.05 | 100 | $13,405.00 | 2,284,015 | SEC Form 4 |
| AFEYAN NOUBAR | MRNA | Director | Jun 18 '24 | Sell | $132.22 | 1,700 | $224,781.65 | 2,312,315 | SEC Form 4 |
| AFEYAN NOUBAR | MRNA | Director | Jun 18 '24 | Sell | $133.26 | 6,160 | $820,887.14 | 2,306,155 | SEC Form 4 |
| AFEYAN NOUBAR | MRNA | Director | Jun 18 '24 | Sell | $134.09 | 6,840 | $917,197.49 | 2,299,315 | SEC Form 4 |
| AFEYAN NOUBAR | MRNA | Director | Jun 18 '24 | Sell | $135.02 | 200 | $27,003.00 | 2,299,115 | SEC Form 4 |
| AFEYAN NOUBAR | MRNA | Director | Jun 18 '24 | Sell | $136.92 | 100 | $13,692.00 | 2,299,015 | SEC Form 4 |
| Hoge Stephen | MRNA | President | Jun 17 '24 | Sell | $138.16 | 15,000 | $2,072,400.00 | 1,457,089 | SEC Form 4 |
| AFEYAN NOUBAR | MRNA | Director | Jun 12 '24 | Sell | $142.97 | 700 | $100,078.72 | 2,328,315 | SEC Form 4 |
| AFEYAN NOUBAR | MRNA | Director | Jun 12 '24 | Sell | $144.46 | 408 | $58,940.46 | 2,327,907 | SEC Form 4 |
| AFEYAN NOUBAR | MRNA | Director | Jun 12 '24 | Sell | $145.57 | 1,263 | $183,860.97 | 2,326,644 | SEC Form 4 |
| AFEYAN NOUBAR | MRNA | Director | Jun 12 '24 | Sell | $146.55 | 3,031 | $444,187.90 | 2,323,613 | SEC Form 4 |
| AFEYAN NOUBAR | MRNA | Director | Jun 12 '24 | Sell | $147.55 | 6,397 | $943,876.07 | 2,317,216 | SEC Form 4 |
| AFEYAN NOUBAR | MRNA | Director | Jun 12 '24 | Sell | $148.61 | 1,601 | $237,929.41 | 2,315,615 | SEC Form 4 |
| AFEYAN NOUBAR | MRNA | Director | Jun 12 '24 | Sell | $149.39 | 1,400 | $209,149.78 | 2,314,215 | SEC Form 4 |
Latest Moderna Inc. News
MRNA Breaking Stock News: Dive into MRNA Ticker-Specific Updates for Smart Investing
Zacks
11 hours ago
Moderna (MRNA) Stock Before Q2 Earnings: To Buy or Not to Buy?
Zacks
12 hours ago
Beam Therapeutics (BEAM) Soars 7.9%: Is Further Upside Left in the Stock?
Simply Wall St.
13 hours ago
Moderna Insiders Sell US$3.3m Of Stock, Possibly Signalling Caution
Barrons.com
17 hours ago
This Biotech Risk-Taker Created Moderna. Now He’s Harnessing AI.
BioPharma Dive
3 days ago
Novartis invests in bispecifics for cancer; Bob Langer steps down from Moderna board
Zacks
3 days ago
Why Moderna (MRNA) Dipped More Than Broader Market Today
ACCESSWIRE
4 days ago
David Rubenstein Joins Moderna's Board of Directors
Zacks
4 days ago
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
Compare MRNA vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MRNA Moderna Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.